Back to mobile site

More on ARQT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+130.8% Growth)
- Ratings (8.2 Score)
- FDA

Upcoming Events

- Earnings (7/30/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arcutis Biotherapeutics (NQ:ARQT)
Delayed: 26.20 -0.02 (0.08%)
Prev. Close $26.22  
Open$26.40 
52 Wk High$ 
52 Wk Low$ 
Day High$26.46 
Day Low$26.08 
P/E N/A  
EPS$ 
Volume186,685 

Friends, Peers and Foes (?): MIRM, NAMS, TARS, PVLA, AMGN (more...)

Jun 30, 2026 09:17 AM Arcutis launches virtual platform linking patients to dermatologists
Jun 30, 2026 09:15 AM Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
Jun 29, 2026 07:06 PM FDA approves Arcutis' roflumilast cream for plaque psoriasis in children 2+
Jun 29, 2026 07:06 PM FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Jun 17, 2026 08:47 PM Form 4 Arcutis Biotherapeutics, For: Jun 15 Filed by: LIN SUE-JEAN
Jun 17, 2026 08:40 PM Form 4 Arcutis Biotherapeutics, For: Jun 15 Filed by: Welgus Howard G.
Jun 17, 2026 04:09 PM Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
Jun 15, 2026 04:12 PM Form 144 Arcutis Biotherapeutics, Filed by: LIN SUE-JEAN
Jun 15, 2026 04:11 PM Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
Jun 12, 2026 05:55 PM Form 4/A Arcutis Biotherapeutics, For: Jun 05 Filed by: Heron Patrick J
View All Articles

Entities mentioned with ARQT

View All Entities